强生(JNJ) 简介:强生公司于1887年在新泽西州注册成立。强生公司及其子公司从事医疗保健领域各种产品的研发、制造和销售。强生公司是一家控股公司,旗下运营公司几乎遍布全球所有国家。公司的主要重点是与人类健康和福祉相关的产品。公司分为两个业务部门:创新医学和医疗技术。 公司网站: http://www.jnj.com 公司地址:O...
Annual profits - Rate of surprise Created with Highcharts 9.3.3TechnologyTechnologyConsumerCyclicalsConsumerCyclicals Consumer N… Consumer N…HealthcareHealthcareFinancialsFinancials Ene… Ene… Basic Materi… Basic Materi…IndustrialsIndustrialsUtilitiesUtilitiesReal ...
namely its Pharmaceutical, andMedTechsegment. The spinoff holds several advantages. Firstly, by removing the consumer health segment, which is the slowest growing sector among the 3 segments, JNJ can focus its growth on other faster growing sectors. In 2022, the Pharmaceutical ...
其中包括2022年以166亿美元收购Abiomed,以... 分享 评论 赞 资讯 产品涉嫌致癌 强生在美国“赔”了51亿元 强生中国客服这样回应 发表于 06-13 19:11 1025次浏览 2 评论 赞 智通财经 发表于 06-13 16:57 460次浏览 爽身粉致癌案消费者要求法院阻止强生(JNJ.US)子公司破产和解方案 一份法庭文件显示,...
Starting with Q3 2023 sales results. Worldwide sales were $21.4 billion for the third quarter of 2023, an increase of 6.8% versus the third quarter of 2022. Operational sales growth, which excludes the effect of translational currency, increased 6.4% as currency had a positive impact of 0.4 ...
Johnson & Johnson Presents at TD Cowen 45th Annual Healthcare Conference, Mar-04-2025 11:10 AM Mar. 04 More transcripts Press Releases: Johnson & Johnson Johnson & Johnson : 2025 Proxy Statement and additional solicitation materials (Johnson Johnson 2025 Proxy)20h agoPU ...
Sales for the company's medical devices business rose to $7.79 billion, up 12.9% from the second quarter of 2022. J&J said growth came from electrophysiological products, which evaluate the heart's electrical system and help doctors understand the cause of abnormal heart rhythms. Wound closure pr...
11:30AM Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue? (Zacks) 07:52AM Is Johnson & Johnson (JNJ) the Best Non-Tech Stock to Buy Now for Long Term? (Insider Monkey) 07:00AM TREMFYA (guselkumab) subcutaneous (SC) induction data support potential to be...
Annual (Values in U.S.thousands) PreviousNext 09-202306-202303-202312-202209-2022 Sales21,351,00021,519,00020,894,00012,548,00019,996,000 Cost of Goods6,606,0006,462,0006,687,0002,907,0006,172,000 Gross Profit14,745,00015,057,00014,207,0009,641,00013,824,000 ...
公告Annual report [Section 13 and 15(d), not S-K Item 405] 强生资讯 02-17 05:37 288 0 公告Statement of changes in beneficial ownership of securities 强生资讯 02-16 09:57 291 0 公告Additional definitive proxy soliciting materials filed by non-management and Ru ...